logo

TRVI

Trevi Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

TRVI fundamentals

Trevi Therapeutics (TRVI) released its earnings on Nov 13, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.08 (YoY +38.46%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.08
+38.46%
Report date
Nov 13, 2025
TRVI Earnings Call Summary for Q3,2025
  • Clinical Momentum: Positive DDI and TIDAL results support Phase III启动 for IPF慢性咳嗽,2026年上半年启动非IPF-ILD和RCC试验。
  • 财务稳健:$195M现金,支持至2028年开发,Q3净亏损收窄至$11.8M。
  • 战略亮点:孤儿药指定请求中;Phase III设计优化剂量滴定以减少副作用;CHEST会议显示医生对治疗未满足咳嗽需求的强烈兴趣。
  • 市场扩展:非IPF-ILD患者群是IPF的两倍,计划与IPF共用临床和商业化资源。
EPS
Revenue

Revenue & Expenses

Key Indicators

Trevi Therapeutics (TRVI) key financial stats and ratios, covering profitability, financial health, and leverage.
Trevi Therapeutics (TRVI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Trevi Therapeutics (TRVI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Trevi Therapeutics (TRVI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Trevi Therapeutics (TRVI) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Trevi Therapeutics (TRVI) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield